ALDX - CIK 0001341235
The table below shows Aldeyra Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $2.41M | $5.43M | $8.51M | $7.42M | $12.44M | $14.97M |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $1.14M |
| $2.57M |
| $1.66M |
| $3.00M |
| $3.70M |
| $3.04M |
| Operating income | -$3.55M | -$8.00M | -$10.17M | -$10.43M | -$16.14M | -$18.01M |
| Income tax | - | - | - | - | - | - |
| Net income | -$3.45M | -$7.69M | -$9.77M | -$9.93M | -$15.11M | -$16.85M |
| EPS (diluted) | -$0.06 | -$0.13 | -$0.16 | -$0.17 | -$0.25 | -$0.28 |